Literature DB >> 24510172

[Ocular pharmacokinetics: Topical, intravitreal, and systemic drug application].

C H Meyer1, T U Krohne.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24510172     DOI： 10.1007/s00347-013-2930-y

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


× No keyword cloud information.
  8 in total

Review 1.  Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics.

Authors:  Augustinus Laude; Lay Ean Tan; Clive G Wilson; Gerassimos Lascaratos; Mohammed Elashry; Tariq Aslam; Niall Patton; Baljean Dhillon
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

2.  Visual outcomes following macular translocation with 360-degree peripheral retinectomy.

Authors:  James C Lai; Deborah J Lapolice; Sandra S Stinnett; Carsten H Meyer; Luz M Arieu; Melissa A Keller; Cynthia A Toth
Journal:  Arch Ophthalmol       Date:  2002-10

3.  Which treatment is best for which AMD patient?

Authors:  P Kroll; C H Meyer
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

4.  Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).

Authors:  Michael W Stewart; Philip J Rosenfeld; Fernando M Penha; Fenghua Wang; Zohar Yehoshua; Elena Bueno-Lopez; Pedro F Lopez
Journal:  Retina       Date:  2012-03       Impact factor: 4.256

5.  Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans.

Authors:  Tim U Krohne; Zengping Liu; Frank G Holz; Carsten H Meyer
Journal:  Am J Ophthalmol       Date:  2012-07-19       Impact factor: 5.258

6.  Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections.

Authors:  Carsten H Meyer; Stephan Michels; Eduardo B Rodrigues; Annette Hager; Stefan Mennel; Jörg C Schmidt; Hans-Martin Helb; Michel E Farah
Journal:  Acta Ophthalmol       Date:  2010-12-22       Impact factor: 3.761

7.  The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model.

Authors:  Frank G Holz; Jean-François Korobelnik; Paolo Lanzetta; Paul Mitchell; Ursula Schmidt-Erfurth; Sebastian Wolf; Sabri Markabi; Heinz Schmidli; Andreas Weichselberger
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-06       Impact factor: 4.799

8.  Ocular pharmacokinetic/pharmacodynamic modeling for multiple anti-glaucoma drugs.

Authors:  Koji Sakanaka; Kouichi Kawazu; Masahide Tomonari; Takashi Kitahara; Mikiro Nakashima; Koyo Nishida; Junzo Nakamura; Hitoshi Sasaki; Shun Higuchi
Journal:  Biol Pharm Bull       Date:  2008-08       Impact factor: 2.233
  8 in total
  1 in total

1.  Efficacy of systemic administration of riboflavin on a rabbit model of corneal alkali burn.

Authors:  Maksym Żuk; Ekaterina Lobashova; Olga Żuk; Sławomir Wierzba
Journal:  Sci Rep       Date:  2020-10-14       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.